迪哲医药-U
(688192)
| 流通市值：284.75亿 | | | 总市值：287.19亿 |
| 流通股本：4.61亿 | | | 总股本：4.65亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 522,692,723.71 | 252,521,933.82 | 801,135,558.29 | 586,301,134.9 |
| 营业收入 | 522,692,723.71 | 252,521,933.82 | 801,135,558.29 | 586,301,134.9 |
| 二、营业总成本 | 759,304,599.27 | 365,009,076.26 | 1,654,178,465.58 | 1,234,483,936.24 |
| 营业成本 | 20,891,117.11 | 10,290,501.15 | 34,228,877.37 | 25,325,157.63 |
| 税金及附加 | 1,943,609.69 | 981,427.79 | 3,203,005.35 | 2,204,553.79 |
| 销售费用 | 241,165,163.44 | 124,486,649 | 570,792,086.75 | 423,739,702.55 |
| 管理费用 | 77,723,281.44 | 34,324,794.44 | 160,154,685.31 | 116,279,108.6 |
| 研发费用 | 402,031,935.6 | 187,797,243.72 | 855,608,765.67 | 644,235,609.66 |
| 财务费用 | 15,549,491.99 | 7,128,460.16 | 30,191,045.13 | 22,699,804.01 |
| 其中:利息费用 | 16,491,865.99 | 7,595,979.38 | 31,215,788.09 | 23,591,119.1 |
| 其中:利息收入 | 538,903.62 | -287,488.87 | 2,136,412.46 | 1,840,889.36 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 13,673,367.04 | 6,753,808.85 | 25,326,758.27 | 18,554,239.98 |
| 资产处置收益 | 84,070.8 | - | 279.52 | 279.52 |
| 信用减值损失(新) | -679,047 | -278,273 | -1,171,167.94 | -1,006,159.94 |
| 其他收益 | 10,908,778.75 | 9,645,182.39 | 62,524,314.13 | 47,733,361.57 |
| 四、营业利润 | -212,624,705.97 | -96,366,424.2 | -766,362,723.31 | -582,901,080.21 |
| 加:营业外收入 | 162,776.5 | 24,435 | - | - |
| 减:营业外支出 | 314.61 | 314.61 | 763,990.11 | - |
| 五、利润总额 | -212,462,244.08 | -96,342,303.81 | -767,126,713.42 | -582,901,080.21 |
| 减:所得税费用 | 633,292.77 | 359,901.2 | 1,390,731.26 | 52,072.14 |
| 六、净利润 | -213,095,536.85 | -96,702,205.01 | -768,517,444.68 | -582,953,152.35 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -213,095,536.85 | -96,702,205.01 | -768,517,444.68 | -582,953,152.35 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -210,373,370.09 | -95,557,355.51 | -764,049,492.71 | -579,947,780.97 |
| 少数股东损益 | -2,722,166.76 | -1,144,849.5 | -4,467,951.97 | -3,005,371.38 |
| 扣除非经常损益后的净利润 | -231,236,627.35 | -108,832,550.09 | -841,553,000.77 | -630,660,904.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.45 | -0.21 | -1.71 | -1.32 |
| (二)稀释每股收益 | -0.45 | -0.21 | -1.71 | -1.32 |
| 九、综合收益总额 | -213,095,536.85 | -96,702,205.01 | -768,517,444.68 | -582,953,152.35 |
| 归属于母公司股东的综合收益总额 | -210,373,370.09 | -95,557,355.51 | -764,049,492.71 | -579,947,780.97 |
| 归属于少数股东的综合收益总额 | -2,722,166.76 | -1,144,849.5 | -4,467,951.97 | -3,005,371.38 |
| 公告日期 | 2026-08-21 | 2026-04-30 | 2026-03-31 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |